{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:05:06Z","timestamp":1777485906085,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008241","name":"Alder Hey Children's NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Children with immunoglobulin A vasculitis (IgAV Henoch-Sch\u00f6nlein purpura) frequently encounter nephritis (IgAV-N) with 1\u20132% risk of kidney failure. The pathophysiology of IgAV-N is not fully understood with speculation that complement may contribute. The aim of this study was to identify whether urinary complement proteins are increased in children with IgAV-N.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional prospective cohort of children with IgAV were recruited together with controls including healthy children and children with systemic lupus erythematosus (SLE). Patients were subdivided according to the presence of nephritis. Urinary C3, C4, C5, and C5a were measured by enzyme-linked immunosorbent assay (ELISA) and corrected for urinary creatinine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 103 children; 47 with IgAV (37 IgAV without nephritis, IgAVwoN; 10 IgAV-N), 30 SLE and 26 healthy children. Urinary complement C3, C4, and C5 were all statistically significantly increased in all children with IgAV compared to SLE patients (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In patients with IgAV-N, urinary complement C3, C4, C5, C5a were all statistically significantly increased compared to IgAVwoN (C3 14.65\u00a0\u03bcg\/mmol [2.26\u201320.21] vs. 2.26\u00a0\u03bcg\/mmol [0.15\u20133.14], <jats:italic>p<\/jats:italic>\u2009=\u20090.007; C4 6.52\u00a0\u03bcg\/mmol [1.30\u20139.72] vs. 1.37\u00a0\u03bcg\/mmol [0.38\u20132.43], <jats:italic>p<\/jats:italic>\u2009=\u20090.04; C5 1.36\u00a0\u03bcg\/mmol [0.65\u20132.85] vs. 0.38\u00a0\u03bcg\/mmol [0.03\u20130.72], <jats:italic>p<\/jats:italic>\u2009=\u20090.005; C5a 101.9\u00a0ng\/mmol [15.36\u2013230.0] vs. 18.33\u00a0ng\/mmol [4.27\u201333.30], <jats:italic>p<\/jats:italic>\u2009=\u20090.01). Using logistic regression, the urinary complement components produced an outstanding ability to discriminate between patients with and without nephritis in IgAV (AUC 0.92, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Children with IgAV-N have evidence of increased complement proteins present in their urine that may indicate a pathological role and may allow treatment stratification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00467-022-05747-3","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T10:02:39Z","timestamp":1665655359000},"page":"1491-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Sch\u00f6nlein purpura) nephritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Rachael D.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Marro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Northey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Corkhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-2390","authenticated-orcid":false,"given":"Louise","family":"Oni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"5747_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fped.2019.00257","volume":"7","author":"L Oni","year":"2019","unstructured":"Oni L, Sampath S (2019) Childhood IgA vasculitis (Henoch Schonlein Purpura)-advances and knowledge gaps. Front Pediatr 7:257. https:\/\/doi.org\/10.3389\/fped.2019.00257","journal-title":"Front Pediatr"},{"key":"5747_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10157-017-1498-2","volume":"22","author":"P Rianthavorn","year":"2018","unstructured":"Rianthavorn P, Chacranon M (2018) Long-term renal outcome in pediatric glomerulonephritis associated with crescent formation. Clin Exp Nephrol 22:661\u2013667. https:\/\/doi.org\/10.1007\/s10157-017-1498-2","journal-title":"Clin Exp Nephrol"},{"key":"5747_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00467-017-3604-9","volume":"32","author":"JD Delbet","year":"2017","unstructured":"Delbet JD, Hogan J, Aoun B, Stoica I, Salomon R, Decramer S, Brocheriou I, Deschenes G, Ulinski T (2017) Clinical outcomes in children with Henoch-Schonlein purpura nephritis without crescents. Pediatr Nephrol 32:1193\u20131199. https:\/\/doi.org\/10.1007\/s00467-017-3604-9","journal-title":"Pediatr Nephrol"},{"key":"5747_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s11255-009-9701-3","volume":"42","author":"Y Kawasaki","year":"2010","unstructured":"Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, Nemoto K, Tsukagoshi A, Nagasawa K, Hosoya M (2010) The incidence and severity of Henoch-Schonlein purpura nephritis over a 22-year period in Fukushima Prefecture, Japan. Int Urol Nephrol 42:1023\u20131029. https:\/\/doi.org\/10.1007\/s11255-009-9701-3","journal-title":"Int Urol Nephrol"},{"key":"5747_CR5","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.smim.2019.101331","volume":"45","author":"K Kaartinen","year":"2019","unstructured":"Kaartinen K, Safa A, Kotha S, Ratti G, Meri S (2019) Complement dysregulation in glomerulonephritis. Semin Immunol 45:101331. https:\/\/doi.org\/10.1016\/j.smim.2019.101331","journal-title":"Semin Immunol"},{"key":"5747_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","volume":"10","author":"DV Rizk","year":"2019","unstructured":"Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, Wyatt RJ (2019) The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol 10:504. https:\/\/doi.org\/10.3389\/fimmu.2019.00504","journal-title":"Front Immunol"},{"key":"5747_CR7","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.bbrep.2021.101102","volume":"27","author":"A Araumi","year":"2021","unstructured":"Araumi A, Osaki T, Ichikawa K, Kudo K, Suzuki N, Watanabe S, Watanabe M, Konta T (2021) Urinary and plasma proteomics to discover biomarkers for diagnosing between diabetic nephropathy and minimal change nephrotic syndrome or membranous nephropathy. Biochem Biophys Rep 27:101102. https:\/\/doi.org\/10.1016\/j.bbrep.2021.101102","journal-title":"Biochem Biophys Rep"},{"key":"5747_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ki.1991.326","volume":"40","author":"JL Ogrodowski","year":"1991","unstructured":"Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W (1991) Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int 40:1141\u20131147. https:\/\/doi.org\/10.1038\/ki.1991.326","journal-title":"Kidney Int"},{"key":"5747_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1681\/ASN.V114700","volume":"11","author":"Y Morita","year":"2000","unstructured":"Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S (2000) Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 11:700\u2013707. https:\/\/doi.org\/10.1681\/ASN.V114700","journal-title":"J Am Soc Nephrol"},{"key":"5747_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s11255-021-03063-7","volume":"54","author":"A Celik","year":"2022","unstructured":"Celik A, Sarioglu S, Kavuk\u00e7u S (2022) Comparison of clinical, pathological and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis and IgA nephropathy. Int Urol Nephrol 54:1925\u20131932. https:\/\/doi.org\/10.1007\/s11255-021-03063-7","journal-title":"Int Urol Nephrol"},{"key":"5747_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00467-019-04445-x","volume":"35","author":"C Dumont","year":"2020","unstructured":"Dumont C, Merouani A, Ducruet T, Benoit G, Clermont MJ, Lapeyraque AL, Phan V, Patey N (2020) Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schonlein purpura. Pediatr Nephrol 35:843\u2013850. https:\/\/doi.org\/10.1007\/s00467-019-04445-x","journal-title":"Pediatr Nephrol"},{"key":"5747_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D\u2019Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:902\u2013906. https:\/\/doi.org\/10.1093\/rheumatology\/keh624","journal-title":"Rheumatology (Oxford)"},{"key":"5747_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12969-018-0230-4","volume":"16","author":"EMD Smith","year":"2018","unstructured":"Smith EMD, Yin P, Jorgensen AL, Beresford MW (2018) Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study. Pediatr Rheumatol Online J 16:14. https:\/\/doi.org\/10.1186\/s12969-018-0230-4","journal-title":"Pediatr Rheumatol Online J"},{"key":"5747_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.molimm.2022.01.011","volume":"143","author":"J Damman","year":"2022","unstructured":"Damman J, Mooyaart AL, Bosch T, Seelen MA, Doorn MBV (2022) Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: a new target for therapy? Mol Immunol 143:114\u2013121. https:\/\/doi.org\/10.1016\/j.molimm.2022.01.011","journal-title":"Mol Immunol"},{"key":"5747_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0272-6386(00)70192-2","volume":"35","author":"M Endo","year":"2000","unstructured":"Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M (2000) Complement activation through the lectin pathway in patients with Henoch-Schonlein purpura nephritis. Am J Kidney Dis 35:401\u2013407. https:\/\/doi.org\/10.1016\/s0272-6386(00)70192-2","journal-title":"Am J Kidney Dis"},{"key":"5747_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/art.1780390716","volume":"39","author":"S Manzi","year":"1996","unstructured":"Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA Jr, Ramsey-Goldman R (1996) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178\u20131188. https:\/\/doi.org\/10.1002\/art.1780390716","journal-title":"Arthritis Rheum"},{"key":"5747_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.7861\/clinmed.2019-0452","volume":"20","author":"J Willows","year":"2020","unstructured":"Willows J, Brown M, Sheerin NS (2020) The role of complement in kidney disease. Clin Med (Lond) 20:156\u2013160. https:\/\/doi.org\/10.7861\/clinmed.2019-0452","journal-title":"Clin Med (Lond)"},{"key":"5747_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000431278","volume":"1","author":"L Bao","year":"2015","unstructured":"Bao L, Cunningham PN, Quigg RJ (2015) Complement in lupus nephritis: new perspectives. Kidney Dis (Basel) 1:91\u201399. https:\/\/doi.org\/10.1159\/000431278","journal-title":"Kidney Dis (Basel)"},{"key":"5747_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2020.1775928","volume":"31","author":"K Ohmura","year":"2021","unstructured":"Ohmura K (2021) Which is the best SLE activity index for clinical trials? Mod Rheumatol 31:20\u201328. https:\/\/doi.org\/10.1080\/14397595.2020.1775928","journal-title":"Mod Rheumatol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05747-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:16:17Z","timestamp":1680095777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05747-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5747"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05747-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author LO has previously undertaken expert advisory work for Omeros Corporation and Biocryst Pharmaceuticals Inc., who are developing drugs to target the complement system. All other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}